![[Lung Cancer Advanced Treatment] A New Height in Immunotherapy: Tiragolumab Combined with Tecentriq Demonstrates Exce...](/_next/image?url=%2Fimages%2Fblog%2Flungcancerusetiragolumabplustecentriq-0.webp&w=3840&q=75)
[Lung Cancer Advanced Treatment] A New Height in Immunotherapy: Tiragolumab Combined with Tecentriq Demonstrates Excellent Efficacy in the CITYSCAPE Trial
[Lung Cancer Advanced Treatment] Tiragolumab Combination Therapy: Opening a New Chapter in TIGIT-Targeted Immunotherapy
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
In non-small cell lung cancer (NSCLC) immunotherapy, while PD-1/PD-L1 inhibitors have become the standard of care, scientists continue to explore "accelerators" that can further enhance immune responses. The anti-TIGIT antibody Tiragolumab is currently one of the most highly anticipated agents. Data from the CITYSCAPE trial published in The Lancet Oncology provides strong evidence for the "dual immune blockade" strategy.
I. The CITYSCAPE Trial: Advantages of Dual-Target Combination
This randomized, double-blind trial enrolled previously treated patients with PD-L1-positive NSCLC without specific gene mutations, comparing "Tiragolumab + Tecentriq" versus "placebo + Tecentriq."
Core Clinical Data:
- Objective Response Rate (ORR): The combination group achieved 31.3%, nearly double the monotherapy group (16.2%).
- Progression-Free Survival (PFS): The combination group median was 5.4 months, significantly better than the monotherapy group's 3.6 months, with a 43% reduction in mortality risk.
- Greater Benefit with High PD-L1 Expression: In the PD-L1 TPS ≥ 50% subgroup, the combination therapy advantage was even more pronounced, demonstrating the value of precise patient selection.
II. Synergistic Mechanism of TIGIT and PD-L1
The combination of Tiragolumab and Tecentriq is a "complementary strategy":
- Tecentriq: Releases the PD-L1 brake on the immune system.
- Tiragolumab: Blocks the TIGIT receptor, further unleashing the killing power of NK cells and T cells. This dual mechanism more comprehensively dismantles cancer cells' immune evasion strategies.
III. Safety and Observations from Japanese Medical Teams
The trial showed that adverse events in the combination therapy group were similar to the monotherapy group, demonstrating good safety. Leading Japanese hospitals are closely tracking multiple global TIGIT-related trials and have extensive experience in managing immune combination therapy, enabling timely intervention for mild inflammatory reactions that occur during treatment.
Medical Supporter Connects You with Global Advanced Immunotherapy Immunotherapy advances rapidly. If you wish to understand the latest applications of TIGIT-targeted drugs in Japan, or seek a second opinion for PD-L1-positive lung cancer, Medical Supporter's team can assist you in translating detailed reports and connecting with Japan's leading experts to plan the most advanced treatment approach for you.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4